Overview

Absorption, Distribution, Metabolism and Excretion of [14C] Labelled BIA 5-1058

Status:
Completed
Trial end date:
2019-05-02
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the mass balance recovery in expired air, urine and faeces after a single oral dose of 400 mg 14C-labeled BIA 5-1058; to provide plasma, urine and faecal samples for metabolite profiling and structural identification; and determine the routes and rates of elimination of [14C]-BIA 5-1058
Phase:
Phase 1
Details
Lead Sponsor:
Bial - Portela C S.A.